Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results presented ...

At the AD/PD 2026, Roche showcased new five-year data from the Phase II PASADENA trial (NCT03100149) involving prasinezumab.

Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up from ...

Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...

Hopper OS, the configurable intelligent healthcare operating system powering better performance, experiences and outcomes ...

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ...

Professor Samuel Seidu, a GP and professor at the University of Leicester, looks at the potential benefits of AI in treating ...

Apogee Therapeutics is advancing APG777, an experimental antibody designed to treat moderate-to-severe atopic dermatitis with far fewer injections than existing biologics. Early clinical data show the ...

CEO Rajagopalan stated, “We remain on track to deliver top line 6-month primary endpoint data in early Q4 2026. With this positive feedback now in hand, ahead of schedule, we are on track for De Novo ...

Elevation Marketing reports the healthcare software market, valued at $84 billion, grows rapidly while hospitals make ...

Deepfake images can mislead viewers, upend elections, and instigate violence. They can also, researchers say, disrupt medical ...

Full-year results and business update Transgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility ...